What is Leerink Partnrs’ Estimate for MNMD Q1 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman expects that the company will earn ($0.35) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Several other research firms also recently commented on MNMD. Oppenheimer reiterated an “outperform” rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday. Evercore ISI began coverage on Mind Medicine (MindMed) in a research note on Tuesday. They set an “outperform” rating and a $23.00 target price for the company. Chardan Capital assumed coverage on shares of Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Leerink Partners began coverage on shares of Mind Medicine (MindMed) in a report on Monday, October 14th. They set an “outperform” rating and a $20.00 target price for the company. Ten analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $26.33.

Mind Medicine (MindMed) Trading Down 4.8 %

Shares of NASDAQ:MNMD opened at $6.79 on Thursday. Mind Medicine has a 12-month low of $3.82 and a 12-month high of $12.22. The company has a market capitalization of $497.92 million, a PE ratio of -3.00 and a beta of 2.60. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $7.26 and its 200-day simple moving average is $6.93.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its earnings results on Thursday, November 7th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. During the same period in the previous year, the company earned ($0.53) earnings per share.

Insider Buying and Selling

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,106 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $141,957.58. Following the completion of the sale, the chief executive officer now directly owns 526,666 shares in the company, valued at $3,913,128.38. This represents a 3.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Dan Karlin sold 6,643 shares of Mind Medicine (MindMed) stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares in the company, valued at $2,511,436.59. This represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,022 shares of company stock worth $208,203. 2.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock valued at $9,548,000 after buying an additional 162,933 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Mind Medicine (MindMed) by 142.6% in the third quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock worth $1,057,000 after purchasing an additional 109,152 shares during the period. Barclays PLC grew its position in shares of Mind Medicine (MindMed) by 203.6% during the 3rd quarter. Barclays PLC now owns 136,098 shares of the company’s stock valued at $775,000 after buying an additional 91,271 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Mind Medicine (MindMed) during the 3rd quarter worth approximately $337,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Mind Medicine (MindMed) during the third quarter valued at $298,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.